China’s Drug Master Files (DMFs) are reviewed by the National Medical Products Administration (NMPA). The process involves evaluating the quality, safety, and efficacy of the drug substances. The NMPA assesses technical data, manufacturing processes, and compliance with regulatory standards to ensure the product meets Chinese pharmaceutical requirements before approval.